Apogem Capital’s HealthEquity HQY Stock Holding History

Apogem Capital’s Portfolio HQY Stock Details HQY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,487	Closed	-$614K	–	188
2021 Q3	$614K	Sell	9,487 -1,000	-10%	-$69.4K	0.39%	94
2021 Q2	$844K	Buy	10,487 +6,456	+160%	+$492K	0.54%	67
2021 Q1	$274K	Sell	4,031 -1,208	-23%	-$94.9K	0.19%	142
2020 Q4	$365K	Buy	+5,239	New	+$326K	0.24%	120

Other funds holding HQY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Apogem Capital's HQY Position: Q4 2021 in Review

Apogem Capital sold out of HealthEquity (HQY) in Q4 2021, closing a stake of 9,487 shares — an estimated $614K sold.

Apogem Capital first reported a position in HQY in Q4 2020 and held it in 4 quarters. The position peaked at $844K in Q2 2021. 282 funds tracked by Wall St. Rank hold HQY as of Q4 2021.

Apogem Capital reported no remaining HealthEquity position as of Q4 2021 after selling out during the quarter.
Apogem Capital sold 9,487 HealthEquity shares in Q4 2021, an estimated $614K.
Apogem Capital first reported a position in HealthEquity in Q4 2020 and held it in 4 quarters.
Apogem Capital's HealthEquity position peaked at $844K in Q2 2021.
282 funds tracked by Wall St. Rank held HealthEquity as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.